阿托伐他汀序贯疗法对不稳定型心绞痛PCI术后临床疗效影响

Effects of sequential therapy of atorvastatin on clinical effectiveness and hs-CRP in patients with unstable angina treated by percutaneous coronary intervention

目的评价阿托伐他汀序贯疗法对不稳定型心绞痛患者PCI术后高敏C-反应蛋白(hs-CRP)、血脂、临床预后及安全性的影响。方法阿托伐他汀序贯治疗组(观察组)80例,常规阿托伐他汀治疗组(对照组)76例,观察组入院给予阿托伐他汀80mg顿服,PCI术前2h再次顿服阿托伐他汀40mg,术后继续服用阿托伐他汀40mg/d,1个月之后减为阿托伐他汀20mg/d;对照组阿托伐他汀20mg/次,1次/d,观察PCI治疗前后血脂、hs-CRP水平及不良事件发生情况。结果两组PCI术前、后TC、LDL-C、TG及hs-CRP水平与治疗前相比,均有降低(P<0.05);观察组与对照组相比,治疗后观察组上述指标降低更明显(P<0.05);观察组不良事件也低于对照组(P<0.05)。结论阿托伐他汀续贯疗法可以进一步强化调脂,降低hs-CRP水平,降低不良事件,改善患者预后。

Objective To evaluate the effects of sequential therapy of atorvastatin on clinical effectiveness and hs CRP in patients with unstable angina treated by percutaneous coronary intervention. Methods Totally 156 patients with high risk unstable angina were randomized into two groups. 80 patients in study group were treated with sequential therapy of atorvastatin and 76 patients in control group were treated with routine therapy of atorvastatin. Both groups were treated continuously for 1 month. Blood lipids, hs CRP and major cardiovascular events were observed. Results TC, LDL C, TG and hs CRP were significantly decreased in both groups after the treatment （ P 〈 0.05 ）. The descendent level of TC,LDL C,TG and hs CRP in the study group was better than the control group （P 〈0. 05）. The occurrence of ma jor cardiovascular events in the study group was significantly lower than that of the control group （ P 〈 0. 05 ） Conclusion Sequential therapy of atorvastatin could not only intensively lowered blood lipids, but also reduced level of hs CRP and major cardiovascular events.